FOXO4-DRI for Health & Longevity

Evidence Review created on 10/25/2026 using AI4L / Opus 5.5

Also known as: FOXO4 D-Retro-Inverso, FOXO4 Peptide, FOXO4-p53 Interfering Peptide, Proxofim

Motivation

FOXO4-DRI is a laboratory-made peptide — a short chain of amino acids — built to kill worn-out cells that have stopped dividing but refuse to die. Such cells build up in tissue with age and leak signals that inflame the cells around them. The peptide draws attention because clearing these cells is one of the few approaches that has been tested against several signs of ageing at once in animals.

The idea grew out of work on how these lingering cells stay alive. Researchers identified a molecular switch that keeps them from self-destructing, designed a peptide to block it, and tested the result in aged mice and in human cells grown in the laboratory. Later work extended the testing to lung and reproductive tissue, and a company was formed to develop the approach. The compound is sold online as a research chemical, and some people inject it.

This review examines what the published record on FOXO4-DRI shows and does not show: what has been measured, in which species, how the compound is thought to work, which harms have been reported or proposed, and what is known about obtaining and handling it.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No Grokipedia article exists for FOXO4-DRI. The site’s search returns only pages on the broader gene and on the drug class, neither of which is a dedicated article on the peptide.

Examine

No Examine article exists for FOXO4-DRI. Examine covers dietary supplements and nutrients; FOXO4-DRI is an unapproved experimental peptide sold as research material rather than as a supplement, which is why it falls outside the site’s scope.

ConsumerLab

No ConsumerLab article exists for FOXO4-DRI. ConsumerLab tests retail supplements for identity and purity; FOXO4-DRI is not sold as a supplement but as an unapproved research chemical, so no product of this kind enters its testing programme.

Systematic Reviews

No systematic reviews or meta-analyses for FOXO4-DRI were found on PubMed as of October 25, 2026. Neither side of the compound’s central trade-off is represented: there is no systematic review or meta-analysis of the claimed benefit (clearing senescent cells to restore tissue function) and none of the principal risk (removing senescent cells that hold tissue barriers together).

Mechanism of Action

Worn-out cells enter senescence (a permanent halt to cell division) rather than dying, and FOXO4 (forkhead box O4, a protein that switches genes on and off) accumulates in them. In senescent cells FOXO4 collects beside unrepaired DNA damage and binds p53 (a protein that decides whether a damaged cell arrests or self-destructs), holding p53 in the nucleus where it drives arrest instead of death (Baar 2017; its authors patented the peptide and founded Cleara Biotech).

FOXO4-DRI is a fragment of the FOXO4 region that contacts p53, rebuilt from D-amino acids in reversed sequence — the D-retro-inverso design, which resists enzyme breakdown — and fused to the arginine-rich TAT sequence (a carrier taken from HIV that ferries cargo across cell membranes). It out-competes native FOXO4 for p53, pushing active p53 out of the nucleus, lowering p21 (a brake on cell division), and triggering self-destruction through caspase-3 and caspase-7 (enzymes that dismantle a dying cell) (Baar 2017).

Two mechanistic readings compete: the original credits competition for p53. Structural work shows the peptide binds p53’s disordered second activation region, and that the TAT carrier contributes, so part of the effect may not be FOXO4 mimicry (Bourgeois 2025).

Pharmacologically, little is pinned down. No human half-life, distribution or metabolism study exists; the D-amino acid backbone is not a substrate for the liver enzymes that clear small-molecule drugs, and the peptide remained detectable in treated cells for 72 hours. Selectivity in culture was roughly twelvefold for senescent over normal human fibroblasts (connective-tissue cells) (Baar 2017).

Historical Context & Evolution

FOXO4 was not discovered as a drug target. It was identified as a member of the forkhead box O family, studied through the 1990s and 2000s for its role in insulin and insulin-like growth factor signalling and in handling reactive oxygen species. Mice lacking it show no striking phenotype, and it is only faintly expressed in most tissues — the two facts that later made it attractive to target.

The therapeutic idea came from elsewhere. Genetic removal of senescent cells was shown to delay age-associated disorders in mice, and the first small-molecule senolytics followed in 2015. In 2017 a group at Erasmus University Medical Center, with the Buck Institute, published the FOXO4 peptide, reporting effects on kidney function, fur density and activity in two mouse ageing models (Baar 2017). The peptide was placed under patent application in the same paper, and Cleara Biotech was founded in 2018 to commercialise it.

Nine years on, the findings remain unreplicated outside animal and cell work, and no independent group has reproduced the in-vivo ageing results. Interpretation has shifted in both directions: structural work refined the binding model (Bourgeois 2025), a rationally redesigned successor peptide was reported (Le 2021), and evidence emerged that clearing certain senescent cells harms mice (Grosse 2020). Cleara’s own published pipeline now lists two optimised oncology candidates rather than FOXO4-DRI (Cleara Biotech pipeline).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the class of evidence required — a clinical endpoint or a validated clinical surrogate measured in human trials from more than one independent research group — does not exist for this compound, because no human trial of any size has been run.

Medium 🟩 🟩

No benefit reaches Medium: there is no single human trial, and no observational human data with a comparison group, of any outcome for this compound.

Low 🟩

No benefit reaches Low: the class of evidence that would qualify — uncontrolled human outcome data such as a case series or case reports — has not been published either; the only human-related reports are undocumented online self-experiments with no measured endpoints.

Speculative 🟨

Restored Kidney Filtration

Clearing senescent kidney tubule cells lowered blood urea in fast-ageing and naturally aged mice, and creatinine in the naturally aged group (Baar 2017). Mouse-only; no human kidney outcome has been measured.

Reduced Frailty Measures

Fur density, responsiveness to touch and voluntary wheel running increased in treated fast-ageing mice (Baar 2017). These are rodent frailty surrogates, individual variation was wide, and no human equivalent was tested.

Protection Against Chemotherapy Tissue Damage

Dosing after doxorubicin blunted weight loss and the rise in a liver-damage enzyme in mice (Baar 2017). Animal-only, one research group, and tested only against doxorubicin.

Three alternate-day injections raised serum testosterone, and later work improved sperm measures, in naturally aged male mice (Zhang 2020, Li 2024). Mouse-only; no human hormone data exist.

Improved Vascular Function ⚠️ Conflicted

Aortic function improved in aged and fast-ageing mice (Hu 2025), yet the same peptide worsened pulmonary vessel disease and depleted lung endothelial (vessel-lining) cells (Born 2023). Net: direction depends on the vessel bed.

Selective Killing of Senescent Human Cells in Culture

Over half of senescent expanded human chondrocytes (cartilage cells) were removed, and senescent keloid scar cells were pushed into self-destruction (Huang 2021, Kong 2025). Culture only; cartilage formation did not improve.

Reduced Lung Fibrosis in Animal Models ⭕️ Not Central to Health & Longevity

Bleomycin-injured mice deposited less scar tissue after treatment (Liu 2023, Han 2022). This bears on treating established fibrotic lung disease, not on healthy-ageing outcomes.

Benefit-Modifying Factors

Senescent-cell burden at baseline: The peptide spared low-passage cells and normal cells while killing senescent ones, so a person carrying few senescent cells has little for it to act on; in mice burden rises steeply only from mid-life onward (Grosse 2020).
Strength of the inflammatory signal from senescent cells: Potency in culture rose when senescent cells were driven to secrete more inflammatory signal and fell when that signal was suppressed, so a low-inflammation state may blunt any effect (Baar 2017).
TP53 genotype and MDM2 variants: The effect runs entirely through p53. Variants altering its activity — TP53 codon 72 (the gene for p53) and MDM2 SNP309 (which raises levels of p53’s main degrader) — would plausibly shift response; neither has been tested here.
Sex: FOXO4 sits on the X chromosome, and the only organ-level animal results outside kidney and lung come from male reproductive tissue (Zhang 2020). Nothing comparable has been measured in females.
Chronological and biological age: Every positive animal result came from aged or prematurely aged animals, which were the only animals treated; non-senescent cells were untouched in culture (Baar 2017). Benefit, if real, concentrates at the older end of the target range.
Pre-existing cancer or precancerous lesions: Senescence restrains damaged cells from dividing. Pushing those cells into death instead could in principle alter tumour behaviour in either direction; the peptide’s successors were developed precisely as anticancer agents (Le 2021).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the class of evidence required — documented adverse events or a validated clinical surrogate in human trials from more than one independent research group — does not exist, because no human trial of this compound has ever been run.

Medium 🟥 🟥

No risk reaches Medium: there is no single human trial and no comparison-group observational human data on harms from this compound, and no harm has been shown for the same compound at a higher dose or for the same carrier with a different payload.

Low 🟥

Endotoxin, Impurity and Dose Error from Unregulated Supply

The only available material is sold as research chemical. Analogous unregulated injectables carried bacterial endotoxin (a fever- and inflammation-triggering bacterial cell-wall fragment) and grossly wrong purity and content (Ashraf 2024), and endotoxin-contaminated counterfeit injectable caused an inflammatory outbreak in patients (Wang 2013). Evidence is indirect: different compounds, same supply chain.

Magnitude: 80 of 116 patients injected from three vials of endotoxin-contaminated counterfeit product developed acute inflammation within a median 12 hours (no control group), and 63 of those 80 regained pre-injection vision (Wang 2013); in purchased unregulated peptide vials, measured purity was 7.7–14.4% against 99% claimed and endotoxin was present in all samples tested (Ashraf 2024).

Speculative 🟨

Removal of Senescent Cells That Hold Tissue Barriers Together

Most p16-high cells (senescence marker) in aged mice lined the liver’s blood vessels; clearing them broke blood-tissue barriers, caused fibrosis and decline, and the cells were never replaced (Grosse 2020). Genetic clearance, not this peptide.

Worsening of Pulmonary Blood-Vessel Disease ⚠️ Conflicted

In mice predisposed to pulmonary hypertension, this peptide raised pulmonary pressures and depleted lung endothelial cells (Born 2023); aortic function improved in aged mice (Hu 2025). Net: harm appears confined to the lung circulation.

Interference with p53 Tumour Surveillance

The peptide binds p53 directly, and p53 is the main brake on damaged cells turning cancerous. A review of the pathway names tumour-surveillance assessment as an unmet prerequisite for human use (Mateescu 2026). Mechanistic only.

Immune Reaction to the Peptide and Its Carrier

Cell-penetrating carriers persist in lymph nodes and raise the immune response to peptides fused to them (Backlund 2022). No immunogenicity data exist for this peptide in any species; the basis is the carrier class alone.

Off-Target Effects of the Arginine-Rich Carrier

Polyarginine cell-penetrating sequences bind and inhibit SERCA2 (a calcium pump central to heart and muscle contraction); the TAT carrier used here did not (Lunde 2023). Isolated tissue only; treated mice showed no cardiac change.

Risk-Modifying Factors

TP53 mutation status: Half of human cancers carry mutant p53. The successor peptides were designed specifically to kill cells with impaired p53 signalling (Cleara Biotech pipeline), so p53 status plausibly determines whether a damaged cell dies or survives after exposure.
Senescent-cell composition, not just burden: Harm in mice tracked which senescent cells were cleared — the endothelial cells lining the liver’s blood channels (sinusoids) proved structurally necessary (Grosse 2020). No test distinguishes necessary from harmful senescent cells in a living person.
Pre-existing pulmonary or hepatic vascular disease: The two documented animal harms were pulmonary endothelial loss (Born 2023) and liver sinusoidal barrier failure (Grosse 2020), so disease already affecting those beds would be expected to raise exposure to the same mechanism.
Sex: No sex-stratified safety data exist in any species for this peptide. FOXO4 is X-linked, which makes a sex difference in expression plausible, and the animal safety work reported no sex breakdown.
Age: Senescent-cell burden, and therefore the amount of tissue affected, rises from roughly mid-life onward in mice (Grosse 2020). At the older end of the target range both the potential effect and the potential for removing load-bearing cells are larger.
Baseline liver and kidney function: Liver enzymes and blood urea were the organ readouts that moved in the animal work (Baar 2017); impairment at baseline would narrow the margin for detecting new injury against existing abnormality.

Key Interactions & Contraindications

Documented interactions:

None identified

Theoretical interactions (inferred from mechanism, not studied in humans):

p53-activating chemotherapy (doxorubicin, cisplatin, etoposide) and radiotherapy: Both push damaged cells toward self-destruction through p53, so co-administration could amplify tissue injury. Animal work deliberately separated them in time, dosing the peptide after chemotherapy rather than alongside it (Baar 2017).
Other senolytics (dasatinib, quercetin, fisetin, navitoclax): Additive clearance of the same cell population, including the senescent endothelial cells that proved structurally necessary in mice. Consequence: greater loss of barrier-forming cells than either agent alone would cause.
p53-pathway drugs (nutlin-3a, idasanutlin, and p53 inhibitors such as pifithrin-α): These raise or suppress p53 activity directly, the same node the peptide acts on, so effect could be amplified or abolished depending on direction.
Corticosteroids (prednisone, hydrocortisone) and interleukin-1 blockers (anakinra, canakinumab): Suppressing the inflammatory output of senescent cells reduced the peptide’s killing potency in culture, so concurrent use would be expected to blunt any effect (Baar 2017).
Over-the-counter anti-inflammatory medication (ibuprofen, naproxen, aspirin): Same inferred mechanism as corticosteroids — damping the inflammatory signal that made senescent cells more vulnerable in culture. Consequence: reduced effect rather than added harm; separating dosing in time is the obvious mitigation.
Anti-inflammatory and senolytic supplements (quercetin, fisetin, curcumin, omega-3 fatty acids, resveratrol): Quercetin and fisetin add senescent-cell clearance; the others damp inflammatory signalling. Consequence: either additive clearance or a blunted effect, depending on which predominates.
Lifestyle interventions with senolytic-like effects (vigorous exercise, prolonged fasting): A systematic review found exercise lowered senescent-cell markers in people and in obese animals (Chen 2021). Consequence: possible additive clearance of the same population.

Populations who should avoid FOXO4-DRI:

Anyone with active or recently treated cancer, or known precancerous lesions: Inferred from the peptide binding p53’s activation region and from the unmet need to assess p53-dependent tumour surveillance (Mateescu 2026); no human data.
People with pulmonary hypertension (mean pulmonary arterial pressure above 20 mmHg, per the 2022 European Society of Cardiology/European Respiratory Society guideline) or chronic hypoxic lung disease: Inferred from worsened pulmonary pressures and lung endothelial loss after this peptide in mice (Born 2023); no human data.
People with established liver fibrosis, cirrhosis or portal hypertension (raised pressure in the liver’s incoming blood vessel): Inferred from barrier failure and hepatic fibrosis after clearance of senescent liver sinusoidal endothelial cells in mice (Grosse 2020); no human data.
People who are pregnant, trying to conceive, or breastfeeding: Inferred from p53’s role in embryonic development together with the complete absence of reproductive or developmental toxicity data in any species; no human data.
Anyone within weeks of surgery, major injury or an unhealed wound: Inferred from the transient repair role of senescent cells during wound healing; no human data.

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

Independent identity, purity and endotoxin testing of any batch: Mitigates the contamination and mislabelling risk. The testing set that exposed failures in comparable products was visual inspection, sterility culture, endotoxin assay and mass spectrometry (Ashraf 2024).
Baseline liver, kidney and blood-count panel, then repeat panels: Mitigates unrecognised organ injury, the harm the animal work tracked through a liver enzyme and blood urea (Baar 2017). Draw before first exposure, at 2 weeks, then every 3 months.
Stop if a liver enzyme exceeds three times the upper limit of normal: Mitigates progression of drug-induced liver injury. That threshold, especially with bilirubin above twice the upper limit, is the recognised signal (FDA drug-induced liver injury guidance).
Watch for fever, malaise or injection-site reaction in the 24 hours after each exposure: Mitigates the immune reaction to the peptide and its arginine-rich carrier, for which no immunogenicity data exist in any species (Backlund 2022).
Age-appropriate cancer screening completed and current before exposure: Mitigates the tumour-surveillance risk, since an undetected lesion is the scenario in which interfering with p53 matters most (Mateescu 2026).
No overlap with other senolytics or with p53-activating chemotherapy: Mitigates additive clearance of barrier-forming cells and amplified tissue toxicity. The animal work separated chemotherapy and peptide in time rather than combining them (Baar 2017).

Therapeutic Protocol

No human protocol for FOXO4-DRI exists. Parameters other than cited doses — timing, cycling and titration — reflect common practice in the animal literature rather than established human practice.

No standard protocol and no practitioner source: Not approved anywhere, and absent from the FDA’s 503A bulk drug substances lists, so it cannot be lawfully compounded. No clinic or prescriber supplies it; no expert-endorsed human regimen is published.
Published animal regimen: Naturally aged mice received 5 mg/kg by abdominal injection every other day for three doses, outcomes read 30 days later (Zhang 2020). The founding work used repeated short cycles rather than continuous dosing (Baar 2017).
Published laboratory concentration: Senescent mouse Leydig (testosterone-making) cells were exposed for three days at that study’s concentration (Zhang 2020). Culture concentrations do not convert to a human dose, and no interspecies scaling for this peptide has been published.
Competing approaches: Other senolytics reached human trials — the Mayo Clinic regimen of dasatinib 100 mg with quercetin 1,000 mg for two consecutive days per cycle (NCT04685590), or fisetin 20 mg/kg on four separate days (NCT04733534). Neither is the default.
Single versus split dosing: Repeated consecutive rounds at lower concentration were more potent against senescent cells in culture than one higher exposure (Baar 2017). Whether this holds in a living human body is untested.
Half-life and persistence: No pharmacokinetic study exists in humans. The D-amino acid backbone resists protein-cutting enzymes, and intracellular peptide remained detectable for at least 72 hours after exposure in culture (Baar 2017).
Time of day: Not studied in any species. No published animal or human work compares morning with evening administration, and no circadian rationale has been proposed for the target.
Genetic variants affecting dose choice: None validated. Because the mechanism runs entirely through p53, TP53 codon 72 and MDM2 SNP309 are the plausible candidates, but neither has been tested against this peptide in any species.
Sex differences: Untested. The only organ-level dosing data outside kidney and lung come from male mice (Zhang 2020), and no female animal or human comparison has been published.
Age: All animal dosing was in aged or prematurely aged animals, with no change in young animals (Baar 2017). No dose adjustment for advanced age has been studied.
Baseline biomarkers influencing response: Potency rose with stronger inflammatory output from senescent cells and fell when it was suppressed (Baar 2017), so inflammatory state is the candidate response marker. No threshold has been defined.
Pre-existing conditions influencing response: Cells with low FOXO4 were untouched in culture (Zhang 2020), and disease states altering p53 signalling would be expected to shift response. None has been studied with this peptide.

Discontinuation & Cycling

Short pulses, not continuous use: Every published regimen is a brief course — three alternate-day injections, or repeated short cycles — rather than ongoing administration (Zhang 2020, Baar 2017). No study has tested lifelong dosing in any species.
No withdrawal effects reported: None have been observed in animal work, but nor has withdrawal been looked for. The mechanism involves no receptor occupancy or hormonal feedback that would predict a rebound on stopping.
Tapering not applicable: With no continuous exposure there is nothing to taper. Animal studies stopped abruptly at the end of each cycle without reported consequence (Baar 2017).
Intermittency is intrinsic, not a chosen cycle: Senescent cells take weeks to re-accumulate, which is the stated rationale for intermittent senolytic dosing generally. No re-dosing interval has been validated for this peptide in any species.

Sourcing and Quality

No lawful source exists: Not approved as a medicine anywhere, and absent from the FDA’s 503A bulk drug substances lists, the route by which a compounding pharmacy could lawfully prepare it. No reputable brand or licensed pharmacy supplies it.
Research-grade material only: What is sold online is labelled research use only and not for human consumption. Such labelling does not reflect pharmaceutical-grade manufacture, and no identity, purity or sterility standard governs what reaches the buyer.
What quality evidence would have to show: Identity and sequence by mass spectrometry, purity by chromatography, sterility by culture, and bacterial endotoxin within limits — the exact set on which comparable unregulated injectables failed badly (Ashraf 2024).
Formulation: Supplied as a lyophilised (freeze-dried) powder requiring reconstitution. Reconstitution outside a sterile environment adds a contamination step that no independent testing of the vial can cover, and no stability data after reconstitution are published.
Supply-chain record: A review of unregulated injectable peptide markets documents contamination, manufacturing impurities and inaccurate dosing as recurring failures across this entire category (Moiz 2026).

Practical Considerations

Time to effect: Unknown in humans. In culture, senescent cells began dying 24–36 hours after exposure; in mice, organ-level readouts were measured 30 days after a three-dose course (Baar 2017, Zhang 2020).
Common pitfall — treating mouse results as transferable: The published effects are rodent and cell-culture findings from largely one research group, with no human replication. Reading them as expected human outcomes is the central error in how this compound is discussed online.
Common pitfall — assuming selectivity equals safety: Selectivity for senescent over normal cells does not mean the senescent cells removed were expendable; in mice, some were structurally necessary (Grosse 2020).
Common pitfall — no way to measure the target: Senescent-cell burden is not a routine clinical measurement, so neither the dose nor the result can be checked. Research assays exist but are not available outside studies.
Regulatory status: Not approved in any jurisdiction, with no marketing authorisation and no prescribing information. It is absent from the FDA’s 503A bulk drug substances lists, so lawful compounding is unavailable.
Cost and accessibility: Access runs only through research-chemical suppliers, which places sourcing, reconstitution and quality assurance entirely on the purchaser. No insurer or health system covers it, and no clinical trial is recruiting for it.

Interaction with Foundational Habits

Sleep: No direct interaction has been studied in any species. The plausible link is indirect: short sleep raises inflammatory signalling, which in culture increased the peptide’s potency against senescent cells (Baar 2017). No timing relative to dosing has been examined, and no sleep outcome was measured in the animal work.
Nutrition: Indirect and potentially blunting. Suppressing the inflammatory output of senescent cells — the effect of corticosteroids and of an interleukin-1 blocker in culture — reduced killing potency (Baar 2017). Strongly anti-inflammatory intakes such as high-dose omega-3 fatty acids or curcumin plausibly do the same; untested.
Exercise: Potentiating, acting on the same target. A systematic review of human and animal studies concluded that exercise lowers senescent-cell markers under certain conditions (Chen 2021). The practical consequence is overlap rather than synergy: both act on one pool, so combined clearance is plausibly larger.
Stress management: Indirect, acting on the substrate. Chronic social stress drove p16-mediated accumulation of senescent cells in mice (Lyons 2025), so unmanaged stress increases the cell population the peptide targets. No study has measured cortisol or stress response after this peptide in any species.

Monitoring Protocol & Defining Success

Because no human data exist, monitoring here is not efficacy confirmation but injury detection. Before any exposure, a liver panel, kidney function with blood urea, a blood count including platelets, and an inflammation marker establish the individual’s own reference points, since there is no population expectation to compare against. Age-appropriate cancer screening belongs in the same baseline, given the p53 mechanism. The same panels then repeat on a fixed cadence — at 2 weeks after a course, at 3 months, and every 3 to 6 months thereafter — because the animal readouts that moved were liver and kidney, and drift in either is the earliest available signal. Success cannot be defined by a target value; the realistic definition is absence of new abnormality against the person’s own baseline, since no biomarker has been linked to a human outcome here.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
ALT and AST	ALT 7–55 U/L; AST 8–48 U/L (standard reference range)	Safety check: liver injury was the organ toxicity the animal work tracked, and a rise is a signal to stop	ALT = alanine aminotransferase; AST = aspartate aminotransferase — enzymes released when liver cells are damaged. Fasting not required. Stop-and-assess at three times the upper limit of normal per FDA drug-induced liver injury guidance
Serum creatinine with eGFR	Creatinine 0.59–1.04 mg/dL (women), 0.74–1.35 mg/dL (men) (standard reference range)	Expected to change: restored kidney filtration was the clearest functional change in treated mice	eGFR = estimated glomerular filtration rate, a calculated measure of filtering capacity. Avoid heavy exercise and large meat intake for 24 hours before the draw; pair with blood urea
Blood urea nitrogen	6–24 mg/dL (standard reference range)	Expected to change: plasma urea was the primary readout of restored kidney function in the animal work	Rises with dehydration, high protein intake and gastrointestinal bleeding, so it is interpreted alongside creatinine rather than alone
Platelet count	150–450 × 10⁹/L (standard reference range)	Safety check: severe platelet loss is the known toxicity of another senolytic class, and platelets were the tolerability check in the animal work; a fall stops use	Drawn in EDTA tubes (EDTA = the tube additive that stops the sample clotting); platelet clumping can falsely lower the result, so a low value is repeated before acting on it
High-sensitivity C-reactive protein	No established target; track change from the individual’s own baseline	Expected to change: the proposed benefit runs through reduced inflammatory signalling from senescent cells	hs-CRP = high-sensitivity C-reactive protein. Published cardiovascular risk bands are risk categories, not a reference range. Do not measure within two weeks of infection or injury
p16INK4a messenger RNA in CD3-positive blood T cells	No established target; track change from the individual’s own baseline	Expected to change: this is the senescent-cell burden measure used as a primary endpoint in senolytic trials	p16INK4a = a protein that accumulates in senescent cells; CD3 = a surface marker identifying T cells. A research assay, not offered by routine laboratories; used as a primary endpoint in NCT04733534
Total testosterone (males)	264–916 ng/dL (standard reference range)	Expected to change: recovery of testosterone output was the clearest organ-level effect in aged male mice	Draw between 07:00 and 10:00 after an overnight fast; a low result is confirmed on a second morning sample before it is treated as real

Qualitative markers worth tracking alongside the laboratory panel:

Energy and fatigue across the day, recorded as a simple daily score rather than recalled at the next visit
Exercise capacity and recovery time after a repeatable effort, since the animal activity findings have no human counterpart
Skin and hair condition, the one visible change reported in the animal work
Sexual function and libido in males, given the testicular findings in aged mice
Injection-site appearance and any fever or malaise in the 24 hours after exposure, the window in which an endotoxin reaction appeared in the counterfeit-product outbreak

Emerging Research

No registered trial of this compound: A ClinicalTrials.gov search on 10/25/2026 for the peptide, its synonyms and its developer returned zero studies. Until one is registered, nothing in this review can move above Speculative, whatever further animal work reports.
Developer’s pipeline has moved on: Cleara Biotech’s published programme now lists two optimised candidates against cancers with impaired p53 signalling, with a stated preclinical-to-clinical strategy in solid tumours, rather than FOXO4-DRI itself (Cleara Biotech pipeline). A clinical filing would be the first human safety read for the chemical class.
Senolytic class trials as the nearest read: A randomised, placebo-controlled trial of dasatinib with quercetin in 48 people with early Alzheimer’s disease is active, estimated completion January 2029 (NCT04685590). A positive safety and biomarker result would support the premise that clearing senescent cells is tolerable in older people; a null result would weaken it.
Frailty in cancer survivors: A randomised trial in 120 adult survivors of childhood cancer compares two senolytic regimens against walking speed and senescent-cell burden, with estimated completion in December 2027 (NCT04733534). Positive function results would raise confidence in the mechanism; a null result would place the animal frailty findings in doubt.
Which senescent cells must be spared: The strongest counterweight is that some p16-high cells are structurally necessary (Grosse 2020). Work identifying harmful from necessary subpopulations could either narrow this compound’s plausible use or rule out indiscriminate clearance entirely.
Structure-guided successors: Solution structures of the peptide bound to p53 now exist (Bourgeois 2025), and a redesigned peptide cleared senescent cells in mice with minimal reported toxicity (Le 2021). This line could make the original peptide obsolete before it is ever tested in people.
Unmet prerequisites named in the literature: A 2026 review of the pathway lists tissue-specific validation, pharmacokinetic and delivery studies, long-term toxicology and explicit assessment of p53-dependent tumour surveillance as conditions for human translation (Mateescu 2026). Each is currently unaddressed.
Possible harm signals to watch: The pulmonary finding was reported by a group independent of the compound’s developers (Born 2023). Replication in another species, or in a lung-disease model, would convert a Speculative risk into a substantive one.

Conclusion

FOXO4-DRI is a synthetic peptide designed to make worn-out, non-dividing cells destroy themselves by breaking a molecular grip that keeps them alive. Nine years after the founding report, the entire evidence base remains animal and cell-culture work: restored kidney filtration, thicker fur, more movement and recovered testosterone output in aged mice, and selective killing of worn-out human cells in laboratory culture. Not one human being has taken it in a registered study, so none of these findings has a human counterpart and all of them sit at the lowest level of confidence this review assigns.

Against that sit three concerns of the same low confidence but real weight: in mice, some of the cells this approach removes turn out to hold tissue barriers together, and losing them caused scarring and decline; the same peptide worsened lung blood-vessel disease in animals predisposed to it; and the protein it manipulates is the body’s main defence against cells turning cancerous. Only one risk rests on human evidence at all, and it concerns the supply rather than the compound — unregulated injectable products have carried bacterial contamination and badly wrong contents.

The evidence base is also narrow in origin. Most of it comes from the group that patented the peptide and the company built around it, and that company’s published programme has since moved to different molecules aimed at cancer. The gap between what has been shown and what is claimed online is wide and remains unmeasured.

Top - Benefits - Risks - Protocol

FOXO4-DRI for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Speculative 🟨

Restored Kidney Filtration

Reduced Frailty Measures

Protection Against Chemotherapy Tissue Damage

Recovery of Age-Related Testosterone Decline

Improved Vascular Function ⚠️ Conflicted

Selective Killing of Senescent Human Cells in Culture

Reduced Lung Fibrosis in Animal Models ⭕️ Not Central to Health & Longevity

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Endotoxin, Impurity and Dose Error from Unregulated Supply

Speculative 🟨

Removal of Senescent Cells That Hold Tissue Barriers Together

Worsening of Pulmonary Blood-Vessel Disease ⚠️ Conflicted

Interference with p53 Tumour Surveillance

Immune Reaction to the Peptide and Its Carrier

Off-Target Effects of the Arginine-Rich Carrier

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion